businesspress24.com - Omni Bio Pharmaceutical to Present at Noble Financial Capital Markets' Eighth Annual Equity Con
 

Omni Bio Pharmaceutical to Present at Noble Financial Capital Markets' Eighth Annual Equity Conference on January 18

ID: 1070948

(firmenpresse) - DENVER, CO -- (Marketwire) -- 01/09/12 -- (OTCBB: OMBP), a clinical-stage biopharmaceutical company, today announced that it will present at Noble Financial Capital Markets' Eighth Annual Equity Conference being held January 17 & 18 at the Hard Rock Hotel & Casino in Hollywood, Florida.

Dr. James Crapo, Omni Bio's chief executive officer, is scheduled to speak on Wednesday, January 18 at 1:30 p.m. Eastern time (11:30 a.m. Mountain time).

Conference and presentation details will be made available at the Omni Bio website at . An archived presentation will be available on the website for 30 days.



Omni Bio Pharmaceutical, Inc. () is a clinical-stage biopharmaceutical company that has licensed potential new indications for an existing FDA approved drug -- Alpha-1 antitrypsin (AAT). Omni Bio's core technology is based on issued patents and patent applications licensed from the University of Colorado Denver (UCD) and a privately held company, Bio Holding, Inc. Omni Bio's lead development program has been funding research and a human clinical trial to evaluate the effectiveness of AAT in the treatment of Type 1 diabetes. Novel discoveries made at UCD indicate that AAT has the potential to address a variety of indications in the areas of diabetes, transplant rejection and bacterial and viral disorders.

Omni Bio is also a significant investor in BioMimetix Pharmaceutical, Inc. (BioMimetix), a recently formed biopharmaceutical corporation. BioMimetix is the exclusive licensee of an issued patent held by Duke University, and intends to develop a new class of patented compounds for the treatment of various diseases including radiation toxicity during the treatment of cancer using radiation therapy.





Omni Bio Pharmaceutical, Inc.
Bob Ogden
Chief Financial Officer - Investor Relations
(720) 488-4708
Email -

WestMountain Asset Management

Steve Anderson - Public Relations




(970) 212-4770
Email -


Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Critical Outcome Technologies Inc. to Meet with Prospective Licensing Partners for COTI-2 at Biotech Showcase
Functional Technologies Engages Momentum Public Relations for Investor Relations
Bereitgestellt von Benutzer: MARKETWIRE
Datum: 09.01.2012 - 08:00 Uhr
Sprache: Deutsch
News-ID 1070948
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

DENVER, CO


Phone:

Kategorie:

Biotech


Anmerkungen:


Diese Pressemitteilung wurde bisher 87 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Omni Bio Pharmaceutical to Present at Noble Financial Capital Markets' Eighth Annual Equity Conference on January 18
"
steht unter der journalistisch-redaktionellen Verantwortung von

Omni Bio Pharmaceutical, Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Omni Bio Pharmaceutical, Inc.



 

Who is online

All members: 10 568
Register today: 1
Register yesterday: 2
Members online: 1
Guests online: 92


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.